title: [Genome instability in pulmonary tuberculosis before and after treatment].
abstract: Pulmonary tuberculosis is classified as a disease with a genetic predisposition, and therefore, as with other pathologies related to this group of diseases, by pulmonary tuberculosis, special importance is given to finding those markers that enable early identification of risk groups, such as skrinnig in general population and relatives of patients with tuberculosis, which in turn can provide the basis for preventive measures. One of this markers is the level of genome stability. The aim of this study was a comparative evaluation of the functional parameters of the genome variability in patients with sensitive form of pulmonary tuberculosis before and after treatment, and the possibility of its correction with anti-stress peptide bioregulator - epitalon. The studies were conducted using short-term mitoge -stimulated cell cultures of TB patients, before and after treatment. As an indicator of genome stability has been studied the frequency of structural and numerical chromosome aberrations and fragile sites. It is shown, that in intact cultures from patients with pulmonary tuberculosis, before treatment was significantly higher level of frequency of cells with structural chromosome aberrations, that still retained after the treatment. As for epithalon, it appears that was shown a pronounced protective effect after treatment, on the test of chromosome aberrations, by reducing both overall mean frequency aberrant cells and indicators for all individuals. In the study of fragility of chromosomes in patients with primary tuberculosis was found, that in intact cultures, the proportion of cells with chromosomal fragile sites was higher than in control group of healthy individuals, befor and after treatment. High frequency of chromosome fragility persisted by treatment with peptide bioregulator in both cases - before and after treatment. It is suggested that the identified patterns can be correlated with a high incidence of re- TB.
authors: T A
authors: TA
authors: Dzhokhadze
authors: T Zh
authors: TZh
authors: Buadze
authors: K Dzh
authors: KD
authors: Rubanov
authors: N A
authors: NA
authors: Kiriia
authors: T A
authors: TA
authors: Lezhava
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage; D002869:Chromosome Aberrations / Q000187:drug effects*; D043283:Chromosome Fragile Sites / Q000187:drug effects; D020022:Genetic Predisposition to Disease; D042822:Genomic Instability / Q000187:drug effects*; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000995:Antitubercular Agents; D009842:Oligopeptides; C421253:alanyl-glutamyl-aspartyl-glycine